Stock Analysis, Dividends, Split History

ADRO / Aduro Biotech, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)494.12
Enterprise Value ($M)399.49
Book Value ($M)176.43
Book Value / Share2.23
Price / Book2.91
NCAV ($M)90.30
NCAV / Share1.14
Price / NCAV5.69
Share Statistics
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 81,006,486
Common Stock Shares Outstanding 77,736,201
Scoring Models
Piotroski F-Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.39
Return on Assets (ROA)-0.21
Return on Equity (ROE)-0.40
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio8.15
Income Statement (mra) ($M)
License And Services Revenue17,109,000.00
Revenue From Grants130,000.00
Operating Income-106.45
Net Income-91.86
Earnings Per Share Diluted-1.26
Earnings Per Share Basic And Diluted-1.26
Earnings Per Share Basic-1.26
Cash Flow Statement (mra) ($M)
Cash From Operations-88.86
Cash from Investing88.94
Cash from Financing-88.86
Identifiers and Descriptors
Central Index Key (CIK)1435049
Related CUSIPS
00739L901 00739L951

Split History

Stock splits are used by Aduro Biotech, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related News Stories

Recent IPO Gritstone Oncology: Neoantigen Targeted Personalized T Cell Therapy In Cancers

2018-10-12 seekingalpha
The company was founded in 2015 by Andrew Allen, who also founded Clovis Oncology and Drs. Tim Chan and Naiyer Rizvi, both from Memorial Sloan Kettering Cancer Center. (8-1)

Aduro Tanks On J&J Partnership Termination Surprise, But Others Remain In Place

2018-10-09 seekingalpha
Aduro's stock tanked after Johnson & Johnson announced the termination of a partnership, however, there are other major partnerships in place. (14-0)

Gritstone Oncology IPO: Data To Be Released In 2019

2018-10-08 seekingalpha
It is quite beneficial that the company was able to seduce a long list of institutional investors. It tells a lot about the company. (9-3)

Janssen Drops Aduro, Too. How Is That Investment Thesis Shaping Up?

2018-10-04 seekingalpha
Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. (37-9)

J&J's Janssen Ends Two Aduro Cancer Collaborations Launched in 2014

2018-10-02 genengnews
Johnson & Johnson’s Janssen Biotech is terminating a pair of collaborations to develop treatments for lung cancer (pictured) and prostate cancer with Aduro Biotech that were launched in 2014 and could have generated more than $1.182 billion for the Berkeley, CA, immunotherapy developer. [Source: NIH]

CUSIP: 00739L101